BioAge Labs (NASDAQ:BIOA) Insider Paul Rubin Sells 7,433 Shares of Stock

BioAge Labs, Inc. (NASDAQ:BIOA) insider Paul Rubin sold 7,433 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

BioAge Labs Trading Down 0.9%

Shares of BIOA stock opened at $19.91 on Wednesday. The firm has a fifty day simple moving average of $14.93 and a two-hundred day simple moving average of $8.96. BioAge Labs, Inc. has a 12 month low of $2.88 and a 12 month high of $24.00. The firm has a market capitalization of $713.77 million, a PE ratio of -13.10 and a beta of 1.42.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Hedge Funds Weigh In On BioAge Labs

Several institutional investors and hedge funds have recently modified their holdings of BIOA. Public Employees Retirement System of Ohio bought a new position in shares of BioAge Labs in the second quarter worth about $57,000. Geode Capital Management LLC grew its stake in shares of BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after buying an additional 171,426 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in shares of BioAge Labs in the second quarter valued at $27,000. Intech Investment Management LLC bought a new stake in BioAge Labs during the second quarter worth $60,000. Finally, Jefferies Financial Group Inc. bought a new stake in BioAge Labs in the 2nd quarter worth about $206,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BIOA shares. Piper Sandler assumed coverage on BioAge Labs in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Citigroup upped their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.00.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.